



## Evolus to Participate in Two Upcoming Investor Conferences

November 1, 2018

IRVINE, Calif., Nov. 01, 2018 (GLOBE NEWSWIRE) -- Evolus, Inc. (NASDAQ:EOLS), a company dedicated to aesthetic medicine, announced today that members of management will be participating in two upcoming investor conferences.

**Event:** Stifel 2018 Healthcare Conference  
**Format:** Presentation & 1x1 Meetings  
**Date:** Tuesday, November 13, 2018  
**Time:** 8:00 a.m. ET presentation  
**Location:** New York, NY

**Event:** Jefferies 2018 London Healthcare Conference  
**Format:** 1x1 Meetings  
**Date:** Wednesday November 14 & Thursday, November 15, 2018  
**Location:** London, UK

An audio webcast of the Company's presentation at the Stifel 2018 Healthcare Conference will be available on the investor relations section of Evolus' website at [investors.evolus.com](http://investors.evolus.com). A replay of the webcast will be available for 90 days after the date of the presentation.

### About Evolus, Inc.

Evolus is a company dedicated to aesthetic medicine focused on providing physicians and their patients with expanded choices in aesthetic treatments and procedures. Evolus' lead candidate DWP-450, also known by the chemical name prabotulinumtoxinA, is a 900 kDa purified botulinum toxin type A complex that was approved by Health Canada for the temporary improvement in the appearance of moderate to severe glabellar lines in adult patients under 65 years of age and is being evaluated for marketing approval in the United States and other areas.

### Evolus Contacts:

#### Investors

Ashwin Agarwal, Evolus  
Tel: +1-949-284-4559  
Email: [IR@Evolus.com](mailto:IR@Evolus.com)

Brian Johnston, The Ruth Group  
Tel: +1 646-536-7028  
Email: [IR@Evolus.com](mailto:IR@Evolus.com)

#### General Media

Kirsten Thomas, The Ruth Group  
Tel: +1-508-280-6592  
Email: [kthomas@theruthgroup.com](mailto:kthomas@theruthgroup.com)

#### Trade Media

Dani Shaffer, Alison Brod Marketing + Communications  
Tel: +1-212-230-1800  
Email: [evolus@alisonbrodmc.com](mailto:evolus@alisonbrodmc.com)



Source: Evolus